Biolase: Letter Perfect?

Bears still expect Biolase BLTI to get it in the teeth.

The dental laser maker seemed to have a real reason to smile late last month. Shares soared in late September when Biolase announced that it had resolved a Food and Drug Administration warning letter.

But a look at the FDA's actual letter suggests that Biolase is the subject of numerous customer complaints that the agency has yet to even examine.

"Not all complaints have been reviewed and evaluated to determine whether an investigation is necessary," the FDA's Sept. 5 letter states. "Specifically, there are at least 325 customer complaints dating back to 10/13/2005 that have not been evaluated to determine if an investigation is necessary."

Even so, Biolase said later last month it had "adequately addressed the FDA's concerns." The company didn't return a call from TheStreet.com seeking comment for this story.

Of course, the last thing Biolase needed to do was give its investors another reason to frown. In recent months, Biolase has seen its domestic sales fall and its foreign sales grow increasingly dependant on a single Korean distributor that has come under fire for its claims about the company's products. Meanwhile, a new competitor -- which secured FDA approval for its own dental laser just this week -- could threaten the company's sales even further.

Despite everything, however, some Wall Street experts continue to recommend the company's stock. Lazard Freres analyst Alexander Arrow upgraded the stock from hold to buy earlier this month -- four days after the company reportedly cleared up its problems with the FDA -- and went on to reiterate that buy rating this week even while acknowledging that the company could face some new competition.

Biolase bears see numerous threats looming. They doubt that Biolase has truly resolved all of its regulatory problems and wonder how the company can hit Wall Street targets in coming quarters. They have sold 28% of the company's stock short in anticipation of a fall.

The shares climbed 1.1% to $6.57 on Wednesday but remain near the low end of their 52-week range.

Miracle Cure

Biolase had to work awfully fast to satisfy the FDA. Just last month, the agency complained about multiple problems at the company.

For starters, the agency said that Biolase leaders had failed to establish a system that ensures the quality of its products. Moreover, the agency said that Biolase had performed no internal quality audits -- as mandated by the company's own rules -- from September 2004 through February 2006.